Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin for prevention of chemotherapy-induced neutropenia in breast cancer
IRCT20250918067285N1Phase 3Completed
- Sponsor
- Razi Broadcasting Company
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of melatonin in breast cancer, sponsored by Razi Broadcasting Company. Primary endpoint: Incidence of neutropenia. Started Sep 2025; status: completed.
02
Drugs
melatonin
03
Conditions
breast cancer
Beyond the preview
Go deeper on IRCT20250918067285N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250918067285N1.